SCHEMBL971837

SCHEMBL971837

Sc1nnc(-c2cnccn2)s1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.49
ALDH1A1 P00352 3/20 0.49
CYP1A2 P05177 1/20 0.49
TERT O14746 6/20 0.44
PIEZO1 Q92508 1/20 0.43
HSD17B10 Q99714 4/20 0.43
HTT P42858 2/20 0.42
RECQL P46063 1/20 0.42
HPGD P15428 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ROCK2 O75116 1/20 0.41
MAPT P10636 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23214179 0.78 TERT (0.52) KDM4EALDH1A1CYP1A2TERTPIEZO1
SCHEMBL2160146 0.77 KDM4E (0.51) KDM4EALDH1A1CYP1A2TERTPIEZO1
SCHEMBL19336777 0.77 KDM4E (0.53) KDM4EALDH1A1CYP1A2TERTPIEZO1
SCHEMBL971007 0.73 KDM4E (0.74) KDM4EALDH1A1CYP1A2HSD17B10HTT
SCHEMBL17225689 0.73 ALDH1A1 (0.52) KDM4EALDH1A1CYP1A2TERTPIEZO1
SCHEMBL15399054 0.73 TERT (0.48) KDM4EALDH1A1CYP1A2TERTPIEZO1
SCHEMBL17225713 0.73 ALDH1A1 (0.49) KDM4EALDH1A1CYP1A2TERTPIEZO1
SCHEMBL8032949 0.72 KDM4E (0.41) KDM4EALDH1A1HSD17B10HPGDNPC1
SCHEMBL12571314 0.72 KDM4E (0.55) KDM4EALDH1A1CYP1A2TERTHSD17B10
SCHEMBL15398639 0.70 KDM4E (0.50) KDM4EALDH1A1CYP1A2TERTPIEZO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4861367-A 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles or 2-mercapto-5-pyrazinyl-1,3,4-thiadiazoles as nematicides CIBA-GEIGY CORPORATION (US) 1989-08-29 US claimed
EP-0290379-A2 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles and -1,3,4-thiadiazoles, process for their preparation and their use as nematicidal agents CIBA-GEIGY AG (CH) 1988-11-09 EP claimed
WO-2021067943-A1 PIEZO1 AGONISTS FOR THE PROMOTION OF BONE FORMATION BIOVENTURES, LLC (US) 2021-04-08 WO disclosed
US-7871982-B2 Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient MEIJI SEIKA KAISHA, LTD. (JP) 2011-01-18 US disclosed
US-20090156512-A1 potent activity against resistant pneumococci MEIJI SEIKA KAISHA, LTD. (JP) 2009-06-18 US disclosed
EP-1970377-A1 LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD. (JP) 2008-09-17 EP disclosed
US-4861367-A 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles or 2-mercapto-5-pyrazinyl-1,3,4-thiadiazoles as nematicides CIBA-GEIGY CORPORATION (US) 1989-08-29 US disclosed
US-4861367-A 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles or 2-mercapto-5-pyrazinyl-1,3,4-thiadiazoles as nematicides CIBA-GEIGY CORPORATION (US) 1989-08-29 US disclosed
US-4861367-A 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles or 2-mercapto-5-pyrazinyl-1,3,4-thiadiazoles as nematicides CIBA-GEIGY CORPORATION (US) 1989-08-29 US disclosed
EP-0290379-A3 2-MERCAPTO-5-PYRAZINYL-1,3,4-OXADIAZOLES AND -1,3,4-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS NEMATICIDAL AGENTS CIBA-GEIGY AG (CH) 1989-02-22 EP disclosed
EP-0290379-A2 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles and -1,3,4-thiadiazoles, process for their preparation and their use as nematicidal agents CIBA-GEIGY AG (CH) 1988-11-09 EP disclosed
EP-0290379-A2 2-Mercapto-5-pyrazinyl-1,3,4-oxadiazoles and -1,3,4-thiadiazoles, process for their preparation and their use as nematicidal agents CIBA-GEIGY AG (CH) 1988-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156512-A1 potent activity against resistant pneumococci H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 KDM4E 3077/4885ALDH1A1 2976/4885CYP1A2 2327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.